5 results
The primary objective is to examine the pharmacokinetics of Nanogam 100 mg/ml and compare these with Nanogam 50 mg/ml. The secondary objective is safety and tolerability of Nanogam 100 mg/ml. Aim is to show bioequivalency between Nanogam 50 mg/ml…
The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.
The results of this study will give better insights in the role of ADMA in the development of systemicendothelial dysfunction and the relation with mild renal insufficiency.
The proportion of patients in GC-free remission after 20 weeks.
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.